PMID- 3041490
OWN - NLM
STAT- MEDLINE
DCOM- 19880908
LR  - 20051116
IS  - 0889-857X (Print)
IS  - 0889-857X (Linking)
VI  - 14
IP  - 1
DP  - 1988 Apr
TI  - Treatment. Disease-modifying therapies.
PG  - 223-43
AB  - Many patients with systemic lupus can be treated effectively with antimalarials 
      and nonsteroidal anti-inflammatory drugs without ever having to take systemic 
      corticosteroids at all or for any significant length of time. On the other hand, 
      some patients with life-threatening disease, active major organ disease, or 
      intolerable corticosteroid toxicities should be given immunosuppressive drugs, 
      plasmapheresis, and/or other therapies in addition to corticosteroids early in 
      their disease course, before permanent, end-organ damage occurs and before the 
      predictable serious and debilitating toxicities of prolonged, daily high-dose 
      corticosteroids develop. Just as lupus patients now routinely undergo detailed 
      serologic testing, it is conceivable that, in the future, routine determination 
      of human leukocyte antigen (HLA) haplotypes45 and T-cell subsets88a will help 
      define, at disease onset, those patients who are destined to have severe disease. 
      Perhaps this knowledge, combined with a better understanding of the exact 
      mechanisms of action of these disease-modifying therapies, will allow a more 
      rational approach to the treatment of SLE.
FAU - Lieberman, J D
AU  - Lieberman JD
AD  - Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
FAU - Schatten, S
AU  - Schatten S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Rheum Dis Clin North Am
JT  - Rheumatic diseases clinics of North America
JID - 8708093
RN  - 0 (Antibodies)
RN  - 0 (Anticoagulants)
RN  - 0 (Antimalarials)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Phospholipids)
SB  - IM
MH  - Antibodies/analysis
MH  - Anticoagulants/therapeutic use
MH  - Antimalarials/adverse effects/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Lupus Erythematosus, Systemic/drug therapy/radiotherapy/*therapy
MH  - Lymphoid Tissue/radiation effects
MH  - Phospholipids/immunology
MH  - Plasmapheresis
MH  - Thrombosis/immunology/therapy
RF  - 131
EDAT- 1988/04/01 00:00
MHDA- 1988/04/01 00:01
CRDT- 1988/04/01 00:00
PHST- 1988/04/01 00:00 [pubmed]
PHST- 1988/04/01 00:01 [medline]
PHST- 1988/04/01 00:00 [entrez]
PST - ppublish
SO  - Rheum Dis Clin North Am. 1988 Apr;14(1):223-43.